Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Xencor, Inc. - Common Stock (NQ:XNCR)

8.330 -0.460 (-5.23%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 9, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Xencor, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
7 Battered Stocks That Could TRIPLE by 2024
While heavily deflated enterprises are usually that way for a reason, speculators may gamble on these battered stocks to buy. 
Via InvestorPlace
Xencor Presents Clinical Results from Phase 1a Study of XmAb®564 at the EULAR 2023 Congress
From Xencor, Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For May 19, 2023
Via Benzinga
What 6 Analyst Ratings Have To Say About Xencor
Via Benzinga
Earnings Outlook For Xencor
Via Benzinga
Why Shares of Zencor Rose This Week
The clinical-stage biotech has seen its shares rise since a company presentation a few weeks ago. 
Via The Motley Fool
Earnings Scheduled For August 3, 2023
Companies Reporting Before The Bell • Cedar Fair (NYSE:FUN) is likely to report quarterly earnings at $1.10 per share on revenue of $512.74 million. 
Via Benzinga
Xencor to Host Second Quarter 2023 Financial Results Webcast and Conference Call on August 3, 2023
From Xencor, Inc.
Via Business Wire
Stocks That Hit 52-Week Lows On Thursday
  On Thursday, 109 companies set new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
  Wednesday's session saw 43 companies set new 52-week lows. 
Via Benzinga
Xencor's Return On Capital Employed Overview
Via Benzinga
Xencor Reports First Quarter 2023 Financial Results
From Xencor, Inc.
Via Business Wire
Earnings Scheduled For May 8, 2023
Companies Reporting Before The Bell • HNI (NYSE:HNI) is likely to report quarterly loss at $0.03 per share on revenue of $462.26 million. 
Via Benzinga
Xencor to Host First Quarter 2023 Financial Results Webcast and Conference Call on May 8, 2023
From Xencor, Inc.
Via Business Wire
Xencor Appoints Nancy Valente, M.D., as Chief Development Officer
From Xencor, Inc.
Via Business Wire
Xencor Highlights CD28 Bispecific Antibody Platform at AACR Annual Meeting 2023
From Xencor, Inc.
Via Business Wire
7 Biotech Stocks to Buy for 100% Returns
If you can handle the risks associated with high volatility, these biotech stocks to buy might double the returns in your portfolio. 
Via InvestorPlace
Xencor to Present Preclinical Data from Novel XmAb® CD28 Bispecific Antibody Programs at the American Association for Cancer Research Annual Meeting 2023
From Xencor, Inc.
Via Business Wire
Xencor Reports Fourth Quarter and Full Year 2022 Financial Results
From Xencor, Inc.
Via Business Wire
Xencor to Report Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call on February 23, 2023
From Xencor, Inc.
Via Business Wire
Top 5 Health Care Stocks That May Collapse In February
The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies. 
Via Benzinga
Xencor to Present at the SVB Securities Global Biopharma Conference
From Xencor, Inc.
Via Business Wire
Earnings Scheduled For February 23, 2023
Companies Reporting Before The Bell • ChipMOS TECHNOLOGIES (NASDAQ:IMOS) is likely to report earnings for its fourth quarter. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 31, 2023
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 30, 2023
Via Benzinga
3 Small-Cap Biopharma Stocks that Could See Big Growth in 2023
Health care stocks are trying to make a comeback and these three small-cap biopharma companies are leading the charge in some ways. 
Via MarketBeat
Xencor Highlights 2023 Corporate Priorities and Provides Portfolio Updates
From Xencor, Inc.
Via Business Wire
Xencor to Present at the 41st Annual J.P. Morgan Healthcare Conference
From Xencor, Inc.
Via Business Wire
Xencor Presents Data from Phase 1 Study of Plamotamab in Relapsed or Refractory Non-Hodgkin Lymphoma at the American Society of Hematology Annual Meeting
From Xencor, Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For December 6, 2022
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.